

Re: Summary of Formulary Changes Effective July 1, 2024.

## **Dear Health Partner:**

We are dedicated to partnering with you to manage our members' care in the most effective way. The CareSource Pharmacy and Therapeutics (P&T) Committee meets regularly to review the Marketplace Drug Formulary and make updates as necessary.

The P&T Committee met recently to update the Formulary. Please review the tables below to see how the Formulary is changing. Additional information about viewing the full Formulary and drug-specific criteria and policies is found at the end of this notice.

Drugs in this table will be added to the Formulary effective July 1, 2024:

DRUG NAME	FORMULARY TIER	COVERAGE LIMITS
Omnitrope liquid/cartridge	4	PA, QL
Naloxone Nasal OTC	1	
Lidocaine 4% OTC Transdermal Patch	1	QL

Drugs in this table have had a <u>change</u> in how they are covered. This could include a change in their Formulary tier and/or adding or removing a coverage limit. The details are shown below.

DRUG NAME	COVERAGE CHANGE
Aptiom	Remains formulary. No Prior Authorization required.
Buprenorphine/Naloxone Sublingual Tablets 2 MG-0.5MG, 8 MG-2 MG	Remains formulary. Quantity Limit removed.
Buprenorphine Sublingual Tablets 2 MG, 8 MG	Remains formulary. No Prior Authorization required. Quantity Limit removed.
Naloxone Nasal Spray 4MG	Remains formulary. Quantity Limit removed.
Narcan Nasal Spray 4MG	Remains non-formulary. Quantity Limit removed.
Suboxone/Buprenorphine-Naloxone Film 12 MG-3 MG	Remains non-formulary. Quantity limit of 2 films/per day
Zubsolv Tablet SL 0.7MG-0.18MG,	Remains non-formulary. Quantity limit of



1.4MG-0.36MG, 2.9MG-0.7MG, 5.7MG-	1 tablet per day
1.4MG, 11.4MG - 2.9MG	
Zubsolv Tablet SL 8.6-2.1 MG	Remains non-formulary. Quantity limit of
	2 tablets per day

Drugs in this table were reviewed by the P&T Committee and will have <u>no</u> <u>changes</u> to their Formulary status. Additional clinical updates are noted below.

DRUG NAME	NOTES
Adakveo	Billed to medical benefit. Hydroxyurea trial length increased to 6 months.
Adbry	Remains formulary. Drug-specific criteria created for age expansion. Quantity limit of 4MLs per 28 days.
Adzynma	Billed to medical benefit. Drug-specific policy created.
Agamree	Remains non-formulary. Drug-specific policy created.
Aldurazyme	Billed to medical benefit. Age limit removed.
Benlysta	Billed to medical benefit. Remains non- formulary pharmacy benefit. No changes.
Cambia	Remains non-formulary. Trial of two preferred NSAIDs required.
Casgevy	Billed to medical benefit. Drug-specific policy created.
Coagadex	Billed to medical benefit. No changes.
Cresemba	Billed to medical benefit. Non-formulary pharmacy benefit. No changes.
Dupixent	Remains formulary. EoE indication age limit 1 year of age and greater than 15kg; updated dosing.
Durysta	Billed to medical benefit. No changes.
Elaprase	Billed to medical benefit. Age limit removed.
Endothelin Receptor Antagonists	Remains non-formulary. Trial of generic
(Letairis, Opsumit, Tracleer)	ERA (ambrisentan or bosentan) required before brand approval.



Fabhalta	Remains non-formulary. Drug-specific	
i abiiala	policy created. Quantity limit of 2	
	· · · · · · · · · · · · · · · · · · ·	
Filsuvez	capsules per day.	
riisuvez	Remains non-formulary. Drug-specific	
Givlaari	policy created.	
	Billed to medical benefit. No changes.	
iDose TR	Medical benefit with medical necessity	
Lucations a	review.	
Imcivree	Remains non-formulary. Initial	
	authorization increased to 12 months.	
	Quantity limit of 10 vials per 30 days.	
Immune Globulin (IVIG and SCIG)	Billed to medical benefit. No changes.	
Infliximab IV	Billed to medical benefit. No changes.	
	Inflectra and Renflexis preferred.	
Jynarque	Remains non-formulary. Quantity limit of	
	2 tablets per day.	
Lupkynis	Remains non-formulary. No changes.	
	Quantity limit of 6 capsules per day.	
Lyfgenia	Billed to medical benefit. Drug-specific	
	policy created.	
Mepsevii	Billed to medical benefit. No changes.	
Naglazyme	Billed to medical benefit. No changes.	
Nexletol / Nexlizet	Remains non-formulary. No changes.	
Ogsiveo	Remains non-formulary. Drug-specific	
	policy created. Quantity limit of 3 tablets	
	per day.	
Oxbryta	Remains non-formulary. Quantity limit of	
	3 tablets per day.	
Oxlumo	Billed to medical benefit. No changes.	
Panhematin	Billed to medical benefit. No changes.	
Qbrexza	Remains non-formulary. No changes.	
Reblozyl	Billed to medical benefit. No changes.	
Relistor	Remains non-formulary. No changes.	
Rivfloza	Billed to medical benefit. Remains non-	
	formulary pharmacy benefit. No changes.	
Rukobia	Remains non-formulary. No changes.	
Ryzumvi	Remains non-formulary. No changes.	
Saphnelo	Billed to medical benefit. No changes.	
Sunlenca	Billed to medical benefit. Remains non-	



	formulary pharmacy benefit. No changes.
Tarpeyo	Remains non-formulary. No changes.
Tegsedi	Remains non-formulary. No changes.
Trogarzo	Billed to medical benefit. No changes.
Vevye	Remains non-formulary. Drug-specific criteria created.
Vimizim	Billed to medical benefit. No changes.
Wainua	Remains non-formulary. Drug-specific policy created.
Wilate	Billed to medical benefit. No changes.
Xphozah	Remains non-formulary. Drug-specific
	criteria created. Requires trial of at least 2 phosphate binders. Quantity limit of 60 tablets per 30 days.
Zilbrysq	Remains non-formulary. Drug-specific policy created.
Zituvio / Zituvimet	Remains non-formulary. Drug-specific criteria created.
Zorvye Foam	Remains non-formulary. Drug-specific criteria created. Quantity limit of 1 can per 30 days.
Zulresso	Billed to medical benefit. No changes.
Zymfentra	Remains non-formulary. Drug-specific criteria created.
Zynteglo	Billed to medical benefit. No changes.

We will provide a list of your CareSource members who are taking any medication upon your request. Please email your request to

<u>PharmacyConversionProgram@CareSource.com</u>. Include the medication names and your secure fax number in your request. We will fax you a list of your patients who have been prescribed these medications.

We know patient care is of the utmost importance to you. We have sent a letter to our members who may be negatively impacted of this change We have recommended that they contact their prescriber if they have questions.

## **Additional Resources**

You can view the full CareSource Marketplace Drug Formulary on the Provider pages at CareSource.com. Select "Drug Formulary" from the Tools and Resources menu under the Providers drop down.



The Drug Formulary page also includes a link to our online Formulary Search Tool where you can find drug coverage criteria and links to applicable clinical and administrative policies.

We recognize each patient is unique, and we appreciate your partnership in transitioning members who may be impacted by the Formulary changes above. We are here to help you with any questions. Call the CareSource Pharmacy Services Department at 833-230-2101. The Pharmacy Department is open Monday through Friday, 8 a.m. to 5 p.m.

Thank you for being a CareSource health partner.

Sincerely, CareSource RxInnovations